The clinical trial for eplontersen is set to end November 2025. You can read more about it here: https://www.clinicaltrials.gov/ct2/show/NCT0413...

Eplontersen, formerly known as IONIS-TTR-LRx and AKCEA-TTR-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to reduce the production of transthyretin, or TTR protein, to treat all types of TTR amyloidosis (ATTR), a systemic, progressive and fatal disease. Patisiran was specifically developed to treat polyneuropathy caused by hereditary Amyloidosis. It may not be as effective at stopping production of TTR as Eplontersen. Ask your Amyloidosis specialty doctor!!

Thanks Paula for more information.

Thank You . Hope this med works well!

Hi, my husband’s cardiologist referred him to a trial for eplontersen for his cardiac amyloidosis(wild type). He was screened and accepted for the trial next week at Columbia Presbyterian in NYC. I think they are still recruiting based on my ‘googling’. I don’t yet know too much about it but will do more research.